https://scholars.lib.ntu.edu.tw/handle/123456789/461615
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHUN-JEN LIU | en_US |
dc.contributor.author | Chang J. | en_US |
dc.contributor.author | PO-HUANG LEE | en_US |
dc.contributor.author | Lin D.-Y. | en_US |
dc.contributor.author | Wu C.-C. | en_US |
dc.contributor.author | Jeng L.-B. | en_US |
dc.contributor.author | Lin Y.-J. | en_US |
dc.contributor.author | Mok K.-T. | en_US |
dc.contributor.author | Lee W.-C. | en_US |
dc.contributor.author | Yeh H.-Z. | en_US |
dc.contributor.author | MING-CHIH HO | en_US |
dc.contributor.author | Yang S.-S. | en_US |
dc.contributor.author | Yang M.-D. | en_US |
dc.contributor.author | Yu M.-C. | en_US |
dc.contributor.author | REY-HENG HU | en_US |
dc.contributor.author | Peng C.-Y. | en_US |
dc.contributor.author | Lai K.-L. | en_US |
dc.contributor.author | Chang S.S.-C. | en_US |
dc.contributor.author | PEI-JER CHEN | en_US |
dc.creator | Chen P.-J.;Chang S.S.-C.;Lai K.-L.;Peng C.-Y.;Hu R.-H.;Yu M.-C.;Yang M.-D.;Yang S.-S.;MING-CHIH HO;Yeh H.-Z.;Lee W.-C.;Mok K.-T.;Lin Y.-J.;Jeng L.-B.;Wu C.-C.;Lin D.-Y.;Lee P.-H.;Chang J.;Liu C.-J. | - |
dc.date.accessioned | 2020-02-19T09:33:45Z | - |
dc.date.available | 2020-02-19T09:33:45Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84909630780&doi=10.3748%2fwjg.v20.i32.11384&partnerID=40&md5=86bd6629ff4cd27bfb0096cea38a0ae9 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/461615 | - |
dc.description.abstract | AIM: To demonstrate that administering heparanase inhibitor PI-88 at 160 mg/d is safe and promising in reducing hepatocellular carcinoma (HCC) recurrence for up to 3 year following curative resection. METHODS: A total of 143 patients (83.1% of the 172 participants in the phase II study) participated in the follow-up study. Of these patients, 50 had received no treatment, 48 had received 160 mg/d PI-88, and 45 had received 250 mg/d PI-88 during the phase II trial. Safety parameters and the following efficacy endpoints were investigated: (1) time to recurrence; (2) disease-free survival; and (3) overall survival. RESULTS: PI-88 at 160 mg/d delayed the onset and frequency of HCC recurrence, and provided a clinically significant survival advantage for up to 3 years after treatment compared with those of the control group: (1) the recurrence-free rate increased from 50% to 63%, and (2) time to recurrence at the 36th percentile was postponed by 78%. The efficacy of administering PI-88 at 250 mg/d was confounded by a high dropout rate (11 out of 54 patients). Additionally, subgroup analyses of patients with (1) multiple tumors or a single tumor ? 2 cm; and (2) hepatitis B or C revealed that administering PI-88 at 160 mg/d conferred the most significant survival advantage (56.8% improvement in disease-free survival, P = 0.045) for patients with both risk factors for recurrence. CONCLUSION: Administering PI-88 at 160 mg/d is a safe and well-tolerated dosage that may confer significant clinical benefits for patients with HCC. ? 2014 Baishideng Publishing Group Inc. All rights reserved. | - |
dc.publisher | WJG Press | - |
dc.relation.ispartof | World Journal of Gastroenterology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | muparfostat; antineoplastic agent; beta glucuronidase; enzyme inhibitor; heparanase; oligosaccharide; phosphomannopentaose sulfate; adult; aged; aminotransferase blood level; Article; bleeding; cancer adjuvant therapy; cancer recurrence; controlled study; disease free survival; drug efficacy; drug safety; female; follow up; hepatitis B; hepatitis C; human; injection site pain; liver cell carcinoma; major clinical study; male; multiple cancer; multiple cycle treatment; neutropenia; overall survival; partial thromboplastin time; patient compliance; phase 2 clinical trial; randomized controlled trial; recurrence free survival; adjuvant chemotherapy; antagonists and inhibitors; Carcinoma, Hepatocellular; clinical trial; drug administration; enzymology; Liver Neoplasms; metabolism; middle aged; mortality; multicenter study; pathology; risk factor; survival; Taiwan; time; treatment outcome; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Glucuronidase; Humans; Liver Neoplasms; Male; Middle Aged; Oligosaccharides; Risk Factors; Survival Analysis; Taiwan; Time Factors; Treatment Outcome | - |
dc.title | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.3748/wjg.v20.i32.11384 | - |
dc.identifier.pmid | 25170226 | - |
dc.identifier.scopus | 2-s2.0-84909630780 | - |
dc.relation.pages | 11381-11393 | - |
dc.relation.journalvolume | 20 | - |
dc.relation.journalissue | 32 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery-NTUHBH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.orcid | 0000-0002-6202-0993 | - |
crisitem.author.orcid | 0000-0001-5831-035X | - |
crisitem.author.orcid | 0000-0003-3660-1062 | - |
crisitem.author.orcid | 0000-0001-6709-031X | - |
crisitem.author.orcid | 0000-0001-8316-3785 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital Bei-Hu Branch | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。